Opioid Use Disorder Flashcards

1
Q

What are the psychosocial treatments of opioid use disorder?

A

Structured counselling
Motivational interviewing
Case management and care coordination
Psychotherapy
Cognitive Behavioural Therapy
Contingency management

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which is more effective: psychosocial tx or pharm?

A

Psychosocial tx + pharm = more effective than either alone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the interaction of trauma, mental health and addictions

A

Most pt’s will have co-occurring mental health disorders or untreated trauma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When caring for an individual with opioid use disorder, what should the focus be on?

A

Start with the person not with the medications

Every individual is a human being: Open to caring for them and meeting the where they are at

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are some of the Canadian OUD guidelines?

A

2017 British Columbia Centre on Substance Use Guidelines
2018 Canadian Research Initiative in Substance Misuse (CRISM) Guidelines

Injectable Opiod Agonist Treatment - More severe spectrum of opioid use disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the clinical management of OUD

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe withdrawal management of OUD

A

Withdrawal management alone is not an effective treatment for opioid use disorder, and offering this as astandalone option to patients is neither sufficient nor appropriate

Similar to tapering off opioids with methadone, agonist taper involving buprenorphine/naloxone appears to reduce the severity of withdrawal symptoms, but the majority of patients still relapse to opioid use if a strategy involving only withdrawal management is employed.

Low intensity treatment is withdrawal management RARELY DO WITHDRAWAL MGT ALONE
–> Referring to completely withdrawing someone with OUD from opiods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the evidence of withdrawal management alone for OUD?

A

Withdrawal management alone is not an effective treatment for OUD and offering as a stand alone is inappropriate or sufficient

Relapse and rates of drop out to opiod use are high regardless of tx modality

Risks of serious harms, including fatal and non-fatal overdose and HIV and Hep-C transmission are higher for individuals who have recently completed withdrawl mgmt compared to individuals who recieved no tx

Withdrawal mgmt, if indicated by patient, should be provided with clear and concise info on the known risks to personal and public safety and be engaged in supportive, constructive discussion about safer tx options

Withdrawl mgmt alone is not recommended unless a discharge plan is in place for refrral to ongoing addiction tx

Much lower abstinence with withdrawal vs. ongoing OAT: instance, participants in the Prescription Opioid Addiction Treatment Study demonstrated significantly lower sustained abstinence rates eight weeks after tapering off buprenorphine/naloxone (8.6%) compared to abstinence rates during buprenorphine/naloxone treatment (49.2%).23

Chronic disease
We can’t just take them off the problematic opioid  Most patients will relapse if just withdrawal them from tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What medication can be used for withdrawal management with OUD?

A

Clonidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe a clonidine taper used in OUD wityhdrawal management

A

Clonidine Taper
Help with physical sx –> Relapse risk is high –> Rarely do this anymore

For most patients with mod-severe (even mild for the most part) will go onto opioid agonist therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the benfits and risks of withdrawal management alone

A

Detox can be an important 1st point of contact and a bridge to other treatment options

However, detox alone associated with:
↑ HIV-transmission
↑ HCV-transmission
↑ Relapse rates
↑ Morbidity
↑ Mortality

Withdraw in hospital for 10 days –> May be extremely desperate to seek opiods if just on RX

Lost tolerance –> Use same amount as before; risk of toxicities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the OUD treatment options

A

Naltrexone –> Opioid antagonist: More use in alcohol use disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the evidence of Naltrexone in OUD

A

Endogenous deficit of opioids –> Need some supplemental opiod –> Not making up deficit of opiods here

Shown that is not helpful for most pt’s in treating SUD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the MOA of naltrexone in OUD

A

Opioid receptor antagonist that blocks the euphoric effects of opioids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the benefits and risks of naltrexone in OUD

A

Benefits:
Ease of administration
No induced tolerance during prolonged tx
No potential for dependence/misuse

Risks:
↑ risk of overdose for patients who stop tx and relapse to opioid use due to ↓ tolerance
mortality 3-7x higher than methadone related mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the formulations and evidence of the various formulations of naltrexone

A

Only oral naltrexone available in Canada
Limited benefit over placebo
2011 meta-analysis found no significant difference in retention or abstinence rates vs. placebo

Extended-release naltrexone monthly IM injections available in US
Improved adherence vs. oral naltrexone
Several RCTs should ↑ retention in tx, ↑ abstinence rates, and ↓ opioid cravings

17
Q

What is the main-stay of OUD treatment?

A

Heart of treatment of opiod use disorder

Suboxone is first line, methadone is 2nd, and slow-release morphine is 3rd line

18
Q

Rank the treatments for OUD: 1st line, 2nd line and 3rd line

A

Buprenorphine/naloxone (Suboxone) now 1st line for OUD treatment

2nd line: methadone

3rd line: slow-release oral morphine

19
Q

Describe the opiate agonist effect of the treatment options for OUD

A

Partial Agonist effect of buprenorphine

20
Q

What is suboxone? What is the dose based upon?

A

Suboxone = buprenorphine + naloxone
Dose based on buprenorphine component

21
Q

Describe the available formulations of suboxone

A

Most will be on SL tabs (buccal film available)

22
Q

Describe the components of suboxone and why they are included?

A

Naloxone – Cant inject it, snort it, or crush it

Prevents diversion–> Fully in there as a diversion mechanism

Buprenorphine is the main drug

Naloxone has 0% bioavailability from the gut

23
Q

Describe the available buprenorphine formulations

A

Buprenorphine patches (Butrans)
Available in Canada
Indication: pain

Buprenorphine/naloxone buccal films (Suboxone)
Newer on the Canadian market as of Jan 2021

Buprenorphine extended release injection (Sublocade)
Indication: OUD
Subcutaneous abdominal monthly injection
Saskatchewan pharmacists with injection training can administer Sublocade!

24
Q

For initiation of Sublocade….

A

Sublocade: patient must be stabilized on buprenorphine containing products

25
Q

Describe the risk of switching between the formulations of Suboxone? Why?

A

Suboxone (buprenorphine and naloxone) and the risk of overdose or underdose when switching between dosage forms or routes of admin

Slight difference in dosing; slight different bioavailability –> need to look at recommendation in product monograph

Start on SL tabs then move to the film

Slight differences in dosing – check cdose on monograph and have close monitoring in place when transitioning

26
Q

Describe the pharmacology of buprenorphine

A

High affinity (strong binding ability) for μ opioid receptor
Displaces heroin or other opiates from receptors
Occupies receptor and blocks other opiates’ effects
Partial agonist at μ opioid receptor
Antagonist a kappa and delta opioid receptors

Slow dissociation (leaving) from opioid receptor
Duration of action increases with increased dose

27
Q

Describe the labelled max of buprenorphine

A

Labelled max =24mg/day but dosed up to 32mg/day for some

28
Q

Describe the duration of action of buprenorphine doses and the duration of action

A

Dose-related increase in duration of action

29
Q

Describe the moa of buprenorphine and an opioid

A

Mu Opiod Receptor: Purple

Sending signals out – withdrawal sx

If give opiod, takes away withdrawal

Yellow: Buprenorphine

Not full effect (euphoria), takes time to get out of the receptor –> protects them from overdose –> people can overcome the effects by using high amounts of substances

But protective safety measure

30
Q

Describe buprenorphine pharmacology agonism and its associated response

A

Partial agonism –> opiate ceiling effects

No further opioid effects above a certain dose

Safer in overdose

31
Q

What is suboxone formulated with? Why?

A

Suboxone formulated with naloxone

Naloxone oral or sublingual is not absorbed

No effect unless injected

May negate opiates effects if injected

32
Q

What are some of the common and other adverse effects of bup/nal?

A

Common:
Headache, pain, withdrawal syndrome
Constipation, nausea, abdominal pain
Insomnia
Runny nose, sweating

Other:
Flu-like symptoms, muscle aches
Tooth disorder, dyspepsia
Depression, anxiety, nervousness, somnolence, dizziness, paresthesia

33
Q

What opioid agonist therapy is the most effective?

A

Suboxone is better tolerated than full opioid agonist therapy